Brigham and Women’s Hospital is recruiting patients for a PHASE2 clinical trial testing immunotherapy for mesothelioma.
The trial, designated NCT05730816, aims to enroll up to 130 participants at 1 sites, including locations in Massachusetts.
About the Study
In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo
.
Treatment Approach
This trial uses checkpoint inhibitor immunotherapy.
Key trial details:
- Phase: PHASE2
- Sponsor: Brigham and Women’s Hospital
- Enrollment target: 130
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- Brigham and Women’s Hospital, Massachusetts
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening